ArticleCardiology research2026
Preheparin Serum Lipoprotein Lipase Mass as a Coronary Risk Factor in Patients With Chronic Kidney Disease.
Article in Cardiology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A significant association between lower preheparin serum lipoprotein lipase mass (pre-LpL mass) and coronary artery disease (CAD) has been reported in several clinical studies. However, the predictor of a pre-LpL mass as a CAD event in patients with chronic kidney disease (CKD) remains unclear. This prospective study aimed to investigate the clinical significance of a pre-LpL mass as a predictor of primary CAD events in patients with CKD. Methods: A total of 480 CKD patients who did not develop CAD among outpatients who visited the clinic were enrolled. Using receiver operating characteristic curve analysis for a primary CAD event, participants were divided into two groups (low pre-LpL mass (group L, n = 211) or high pre-LpL mass (group H, n = 269)) by pre-LpL mass, and significance of a pre-LpL mass as a predictor for the primary CAD events was performed. Results: At baseline, skin autofluorescence, an indicator of advanced glycation end products Conclusions: The prospective study showed that a decrease in pre-LpL mass is a useful predictor of a primary CAD event in patients with CKD. Additionally, background factors such as an increase in advanced glycation end products and inflammation are also an important factor in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.